ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: a cross-sectional study.

BACKGROUND Asymmetric dimethylarginine (ADMA) and subclinical inflammation are associated with atherosclerosis progression, whereas microalbuminuria is an established index of hypertensive organ damage. STUDY DESIGN Cross-sectional. SETTING & PARTICIPANTS In an outpatient hypertensive unit, 296 nondiabetic and untreated participants with hypertension were studied. Participants with atherosclerotic cardiovascular disease, severe valvulopathy, congestive heart failure, presence of neoplastic or other concurrent systemic disease, atrial fibrillation, serum creatinine level > 1.5 mg/dL in men and > 1.4 mg/dL in women, and urinary albumin excretion > 300 mg/24 h were excluded. PREDICTORS ADMA and high-sensitivity C-reactive protein (hs-CRP) levels. OUTCOME VARIABLE Albuminuria assessed using albumin-creatinine ratio (ACR). MEASUREMENTS Participants underwent ambulatory blood pressure monitoring, echocardiography, routine assessment of metabolic profile, ADMA, and hs-CRP, whereas ACR was determined as the mean of 3 values in nonconsecutive morning spot urine samples. RESULTS 64 participants had an ACR of 30-300 mg/g. Stratification based on ADMA level showed that participants with hypertension in quartile [Q] 4 compared with those in Q3, Q2, and Q1 showed the highest ACRs (53.2 vs 31.2 vs 30.4 vs 16.7 mg/g; P < 0.008 for all). Moreover, stratification based on hs-CRP level showed that participants with hypertension in Q4 (69.8% had microalbuminuria) showed the highest ACRs (72.2 vs 25.6, 16.2, and 19.2 mg/g for Q3, Q2, and Q1, respectively; P < 0.008 for all). Stepwise regression analysis showed that age, 24-hour systolic blood pressure, hs-CRP level, ADMA level, and the interaction of hs-CRP with ADMA were independent predictors of ACR (R(2) = 0.674; P < 0.001). LIMITATIONS Cross-sectional study. CONCLUSIONS In patients with untreated essential hypertension, increased hs-CRP and ADMA levels are associated with microalbuminuria, suggesting the involvement of inflammation and endothelial dysfunction in vascular and kidney damage.

[1]  S. Chierchia,et al.  Effect of oral L-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise tests, and normal coronary arteries. , 2004, The American journal of cardiology.

[2]  N. Reichek,et al.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[3]  I. Kallikazaros,et al.  The emerging role of subclinical inflammation in hypertension-associated early renal dysfunction: focus on microalbuminuria. , 2006, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[4]  M. Di Napoli,et al.  Angiotensin-Converting Enzyme Inhibitor Use Is Associated With Reduced Plasma Concentration of C-Reactive Protein in Patients With First-Ever Ischemic Stroke , 2003, Stroke.

[5]  E. Mannarino,et al.  Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures , 2003, Journal of hypertension.

[6]  S. Pede,et al.  Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. , 1998, Hypertension.

[7]  J. Cooke.  Asymmetrical Dimethylarginine: The Über Marker? , 2004, Circulation.

[8]  I. Kallikazaros,et al.  Evidence for no global effect of metabolic syndrome per se on early hypertensive sequelae , 2008, Journal of hypertension.

[9]  Frank Donnerstag,et al.  ADMA Increases Arterial Stiffness and Decreases Cerebral Blood Flow in Humans , 2006, Stroke.

[10]  C. Zoccali,et al.  ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. , 2006, Kidney international.

[11]  C. Zoccali,et al.  ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. , 2003, Atherosclerosis. Supplements.

[12]  D. Tsikas,et al.  Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. , 1999, Journal of cardiovascular pharmacology.

[13]  T. Ogihara,et al.  Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. , 2004, American journal of hypertension.

[14]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  D. Tsikas,et al.  Cardiovascular Effects of Systemic Nitric Oxide Synthase Inhibition With Asymmetrical Dimethylarginine in Humans , 2004, Circulation.

[16]  R. Gans,et al.  C-Reactive Protein Modifies the Relationship Between Blood Pressure and Microalbuminuria , 2004, Hypertension.

[17]  M. Mariani,et al.  Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension , 2002, Journal of Human Hypertension.

[18]  D. Konukoğlu,et al.  The relationship between plasma asymmetrical dimethyl-L-arginine and inflammation and adhesion molecule levels in subjects with normal, impaired, and diabetic glucose tolerance. , 2008, Metabolism: clinical and experimental.

[19]  S. Yusuf,et al.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.

[20]  I. Kallikazaros,et al.  Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. , 2005, The American journal of cardiology.

[21]  D. Fliser,et al.  Asymmetric Dimethylarginine, Blood Pressure, and Renal Perfusion in Elderly Subjects , 2003, Circulation.

[22]  I. Kallikazaros,et al.  Inter-relationships of microalbuminuria with the other surrogates of the atherosclerotic cardiovascular disease in hypertensive subjects. , 2004, American journal of hypertension.

[23]  C. Zoccali.  Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. , 2006, Journal of hypertension.

[24]  B. Hedblad,et al.  Inflammation-Sensitive Plasma Proteins and Incidence of Myocardial Infarction in Men With Low Cardiovascular Risk , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[25]  T. Imaizumi,et al.  Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: an epidemiological study. , 2007, Atherosclerosis.

[26]  D. Fliser,et al.  CARDIOVASCULAR EFFECTS OF SYSTEMIC NITRIC OXIDE SYNTHASE INHIBITION WITH ASYMMETRIC DIMETHYLARGININE IN HUMANS: P 061 , 2004 .

[27]  M. Wolzt,et al.  Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with Type 2 diabetes and albuminuria , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[28]  R. Schmieder,et al.  Angiotensin Converting Enzyme Inhibition and Angiotensin II AT1-Receptor Blockade Reduce the Levels of Asymmetrical NG, NG-Dimethylarginine in Human Essential Hypertension* , 2002 .

[29]  T. Imaizumi,et al.  Roles of Intercellular Adhesion Molecule-1 in Hypertensive Cardiac Remodeling , 2003, Hypertension.

[30]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[31]  C. Zoccali,et al.  Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. , 2002, Kidney international.

[32]  T. Halonen,et al.  Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[33]  C. Zoccali,et al.  Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study , 2001, The Lancet.

[34]  I. Kallikazaros,et al.  Absence of any significant effects of circadian blood pressure variations on carotid artery elastic properties in essential hypertensive subjects , 2000, Journal of Human Hypertension.

[35]  C. Zoccali,et al.  Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. , 2005, Journal of the American College of Cardiology.

[36]  I. Kallikazaros,et al.  Diverse associations of microalbuminuria with C-reactive protein, interleukin-18 and soluble CD 40 ligand in male essential hypertensive subjects. , 2006, American journal of hypertension.

[37]  V. Dzau.  Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. , 2001, Hypertension.

[38]  S. Del Prato,et al.  Low-Grade Inflammation and Microalbuminuria in Hypertension , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[39]  P. Ridker,et al.  Blood Pressure and Inflammation in Apparently Healthy Men , 2001, Hypertension.